Latest Industry Insights

Dr. Andreas Boehmler explores how the arrival of new flow cytometry platforms finally puts powerful automation within reach for many labs, allowing operators to enumerate stem cells more quickly and accurately for transplant.

Discover ways for decarbonization in biobanking and learn how a biobank information management system (BIMS) can reduce the carbon footprint of biobanks.

Technology Networks had the pleasure of speaking with Dr. Maddison Masaeli, co-founder and chief executive officer at Deepcell to learn about the REM-I platform, a single-cell analysis tool that utilizes AI-powered imaging to magnify insights into a cell’s phenotype and function.

We spoke to Prof. Oscar Ces, head of the Department of Chemistry at Imperial College London (ICL), to find out about the evolution of ICL’s White City Campus, the Agilent Measurement Suite and what it means for scientists across the board.

Hans van der Voorn tells us about some of the recent progress in the extracellular vesicle-based diagnostics and therapeutics landscape, particularly the need for industrial-scale EV isolation workflows.

At the 71st Annual Society for Mass Spectrometry (ASMS) meeting, Technology Networks had the pleasure of speaking with Rohan Thakur, president of Life Sciences Mass Spectrometry at Bruker Daltonics. We discussed the new product launches from Bruker and focused specifically on the applications of the company’s newest mass spectrometer, the timsTOF Ultra, for immunopeptidomics.

Renewed efforts to tap cyanobacteria, algae and plants in arenas typically dominated by heterotrophic systems are already beginning to yield fruit. In this article, we explore the inherent value of photosynthetic biotechnologies and their challenges.

In this interview, Technology Networks spoke to Dr. Stuart Marcus, founder and chief medical officer of SonALAsense, to find out how ALA sonodynamic therapy could be a more effective treatment for diffuse intrinsic pontine glioma and recurrent glioblastoma.

In this opinion piece, Liz Sparrow discusses the real risk of the UK losing its science and technology communities as they face a series of challenges that are threatening their growth.

In this opinion piece, Francois Rieger discusses why reverse mergers are the way forward for advanced therapies.